Purification and biochemical characterization of a novel protein - Tongue cancer chemotherapy resistance-associated protein1 (TCRP1)

Protein Expression and Purification

Volumn 82, Issue 2, 2012, Pages 360-367

  Peng, Bo ^a,c   Yi, Sisi ^a   Gu, Yixue ^a   Zheng, Guopei ^a   He, Zhimin ^a,b  

^a Central South University   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Drug resistance; MDR; OSCC; Purification; TCRP1

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; ANTISERUM; BLEOMYCIN; BLEOMYCIN A5; CISPLATIN; DRUG DERIVATIVE; FLUOROURACIL; HYBRID PROTEIN; PROTEIN; TONGUE CANCER RESISTANCE ASSOCIATED PROTEIN 1, HUMAN; TONGUE CANCER RESISTANCE-ASSOCIATED PROTEIN 1, HUMAN;

ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMICAL PHENOMENA; CHEMISTRY; DNA DAMAGE; DRUG EFFECT; DRUG RESISTANCE; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; MOUTH TUMOR; PATHOLOGY; PROTEIN BINDING; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODY SPECIFICITY; BLEOMYCIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMMUNE SERA; MICE; MICE, INBRED BALB C; MOUTH NEOPLASMS; PROTEIN BINDING; PROTEINS; RECOMBINANT FUSION PROTEINS;

EID: 84857731942     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2012.02.002     Document Type: Article

References (28)

1. R.I. Haddad, and D.M. Shin Recent advances in head and neck cancer N. Engl. J. Med. 359 2008 1143 1154
2. D. Chin, G.M. Boyle, S. Porceddu, D.R. Theile, P.G. Parsons, and W.B. Coman Head and neck cancer: past, present and future Expert Rev. Anticancer Ther. 6 2006 1111 1118
3. W.E. Evans, and H.L. McLeod Pharmacogenomics-drug disposition, drug targets, and side effects N. Engl. J. Med. 348 2003 538 549
4. S. Choudhuri, and C.D. Klaassen Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters Int. J. Toxicol. 25 2006 231 259
5. J.D. Allen, and A.H. Schinkel Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2) Mol. Cancer Ther. 1 2002 427 434
6. M.H. Raaijmakers, E.P. de Grouw, L.H. Heuver, B.A. van der Reijden, J.H. Jansen, R.J. Scheper, G.L. Scheffer, T.J. de Witte, and R.A. Raymakers Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia Clin. Cancer Res. 11 2005 2436 2444
7. Y. Yamano, K. Uzawa, K. Saito, D. Nakashima, A. Kasamatsu, H. Koike, Y. Kouzu, K. Shinozuka, K. Nakatani, K. Negoro, S. Fujita, and H. Tanzawa Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma Int. J. Cancer. 126 2010 437 449
8. P. Zhang, Z. Zhang, X. Zhou, W. Qiu, F. Chen, and W. Chen Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line BMC Cancer 6 2006 224
9. G. Zheng, M. Zhou, X. Ou, B. Peng, Y. Yu, F. Kong, Y. Ouyang, and Z. He Identification of carbonic anhydrase 9 as a contributor to pingyangmycin-induced drug resistance in human tongue cancer cells FEBS J. 277 2010 4506 4518
10. Y. Gu, S. Fan, Y. Xiong, B. Peng, G. Zheng, Y. Yu, Y. Ouyang, and Z. He Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line FEBS Lett. 585 2011 881 887
11. Y. Gu, S. Fan, B. Liu, G. Zheng, Y. Yu, Y. Ouyang, and Z. He TCRP1 promotes radioresistance of oral squamous cell carcinoma cells via Akt signal pathway Mol. Cell Biochem. 357 2011 107 113
12. G. Zheng, F. Peng, R. Ding, Y. Yu, Y. Ouyang, Z. Chen, Z. Xiao, and Z. He Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis J. Cancer Res. Clin. Oncol. 136 2010 1477 1488
13. F. Yang, M. Zhou, Z. He, X. Liu, L. Sun, Y. Sun, and Z. Chen High-yield expression in Escherichia coli of soluble human MT2A with native functions Protein Expr. Purif. 53 2007 186 194
14. J. Wang, Y. Zhang, C. Lu, L. Lei, P. Yu, and G. Zhong A genome-wide profiling of the humoral immune response to Chlamydia trachomatis infection reveals vaccine candidate antigens expressed in humans J. Immunol. 185 2010 1670 1680
15. P. Borst, R. Evers, M. Kool, and J. Wijnholds A family of drug transporters: the multidrug resistance-associated proteins J. Natl. Cancer Inst. 92 2000 1295 1302
16. R.G. Deeley, C. Westlake, and S.P. Cole Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins Physiol. Rev. 86 2006 849 899
17. S. Moller, M.D. Croning, and R. Apweiler Evaluation of methods for the prediction of membrane spanning regions Bioinformatics 17 2001 646 653
18. L. Galluzzi, L. Senovilla, I. Vitale, J. Michels, I. Martins, O. Kepp, M. Castedo and G. Kroemer, Molecular mechanisms of cisplatin resistance, Oncogene (2011).
19. J.M. Piulats, L. Jimenez, X. Garcia del Muro, A. Villanueva, F. Vinals, and J.R. Germa-Lluch Molecular mechanisms behind the resistance of cisplatin in germ cell tumours Clin. Transl. Oncol. 11 2009 780 786
20. D.J. Stewart Mechanisms of resistance to cisplatin and carboplatin Crit. Rev. Oncol. Hematol. 63 2007 12 31
21. R.P. Wernyj, and P.J. Morin Molecular mechanisms of platinum resistance. still searching for the Achilles' heel Drug Resist. Updat. 7 2004 227 232
22. L. Benitez-Bribiesca, P. Sanchez, J. Toledo, R. Penarroja, M. Flores, and J. Sosa Differential staining of DNA strand breaks in dried comet assay slides J. Histochem. Cytochem. 49 2001 921 922
23. P. Moller, L.E. Knudsen, S. Loft, and H. Wallin The comet assay as a rapid test in biomonitoring occupational exposure to DNA-damaging agents and effect of confounding factors Cancer Epidemiol. Biomarkers Prev. 9 2000 1005 1015
24. S.L. Kelley, A. Basu, B.A. Teicher, M.P. Hacker, D.H. Hamer, and J.S. Lazo Overexpression of metallothionein confers resistance to anticancer drugs Science 241 1988 1813 1815
25. Y. Kondo, S.M. Kuo, and J.S. Lazo Interleukin-1 beta-mediated metallothionein induction and cytoprotection against cadmium and cis-diamminedichloroplatinum J. Pharmacol. Exp. Ther. 270 1994 1313 1318
26. J.H. Chun, H.K. Kim, E. Kim, I.H. Kim, J.H. Kim, H.J. Chang, I.J. Choi, H.S. Lim, I.J. Kim, H.C. Kang, J.H. Park, J.M. Bae, and J.G. Park Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer Cancer Res. 64 2004 4703 4706
27. A.B. Abdel-Mageed, and K.C. Agrawal Activation of nuclear factor kappaB: potential role in metallothionein-mediated mitogenic response Cancer Res. 58 1998 2335 2338
28. C. Duhem, F. Ries, and M. Dicato What does multidrug resistance (MDR) expression mean in the clinic? Oncologist 1 1996 151 158